New Medidata Report Reveals 70% of AI Users in Clinical Trials See Measurable Gains in Study Speed, Protocol Design, and Data Quality
The results provide essential understanding into how AI is enhancing clinical trial operations and shortening study timelines, helping to shape the future of clinical research
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today released a new global research report, The State of AI in Clinical Trials: Today and Tomorrow, offering a comprehensive look at how artificial intelligence (AI) is redesigning the clinical development landscape. The results, from the Medidata-commissioned study of global clinical research professionals, provide extensive insights into AI adoption, its transformative impact, and tomorrow’s expectations across the clinical trial lifecycle.
The findings, derived from a survey of over 200 global clinical research professionals, include:
- AI is Delivering on its Promise: The vast majority of AI users are seeing benefits. An impressive 73% of AI users note that AI integration has met or surpassed their expectations. This satisfaction is driven by tangible results, including 70% of users who confirm improved data accuracy and 61% who cite streamlined data collection.
- AI is an Imperative Tool, Not a Luxury: The study reveals that 56% of organizations have already adopted AI in some capacity, with only a small minority (7%) indicating no plans for adoption in the next 12 months. This engagement shows AI is moving from a niche technology to a core business necessity.
- AI is Revolutionizing Data Management: AI is stepping in to make it cleaner, faster, and more reliable, with 93% of AI-using companies employing it for data capture and data quality oversight. For a tangible example of this efficiency, Medidata’s AI auto-coding can save up to 69 hours for every 1,000 verbatims.
- AI is Driving Patient Engagement: As trials become more decentralized, AI is becoming essential for refining patient engagement and retention. Over half of AI users leverage the technology for personalized communications, reminders, and chatbots. At the same time, AI is proving highly effective at the front end of the trial process, with 83% of companies using it for patient population and cohort identification to find the right participants from the start.
“The industry has progressed beyond AI Proof of Concepts. Forward-looking organizations are now scaling AI in targeted, high-impact ways,” stated Tom Doyle, chief technology officer, Medidata. “This report underscores how we can leverage AI's potential to expedite the development of new therapies. We are proud to lead this transformation and, alongside our partners, to reimagine our platform and clinical research to create trials that are more efficient, insightful, and ultimately, more successful.”
Access the full report here.
On Oct. 22, Medidata will host an AI webinar, AI Everywhere: Architecting the Future of Clinical Trials, to discuss the current state of AI in the clinical trials space. To register for the webinar, please visit here.
Contact:
Medidata PR
Analyst Relations